Navigation Links
VIVUS Resubmits Qnexa NDA to the FDA
Date:10/17/2011

failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks with development, regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian Korb Chief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923Media Relations:GolinHarrisSusan Brophysbrophy@golinharris.com312-729-4359
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  PCI is pleased to announce it has ... leading provider of Clinical Trial Services and Temperature ... Wales in the United ... presence in the UK/EU to support global investigational ... and distribution capacity, as well as consultative services ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)... , September 18, 2014 ... http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition of ... Report"  report to their offering.  ... the worldwide markets for Sugar Alcohols in ... Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care Products, ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
(Date:9/19/2014)... 2014 Are you tired of having ... with seasonal allergies or sinus congestion? Fortunately, an inventor ... , She conceived of Nose Pal to avoid ... nose in public. Since it prevents nasal drip and ... conditions, particularly when cooking or working closely with others. ...
(Date:9/19/2014)... (HealthDay News) -- As kids transition from elementary to ... according to a recent study. But the ... found that verbal and physical bullying declines as students ... and prevention strategies must address all types of bullying ... girls, the researchers said. The study was published recently ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Your brain structure could help predict ... study suggests. Researchers at Yale University found those with ... the parietal cortex may be more likely to engage in ... , , The study, funded by the U.S. National Institute ... women living in the Northeast. The researchers sought to determine ...
Breaking Medicine News(10 mins):Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2
... Indiana University study found that young, female breast cancer ... and are interested in using sexual enhancement products to ... Cancer Survivors: Their sexual function and interest in sexual ... the journal Cancer Nursing . , The study ...
... reduced chances by 26% , , SUNDAY, Nov. 9 (HealthDay News) ... an extra benefit: a reduction in their risk of developing ... under the age of 52, according to research that was ... in New Orleans. , The findings, the first to demonstrate ...
... to protect healthy men, either , , SUNDAY, Nov. 9 ... doubt on the cardiac benefits of either low-dose aspirin ... low-dose aspirin did not reduce the risk of cardiovascular ... Harvard researchers concluded that neither vitamin E nor vitamin ...
... Low-dose aspirin as primary prevention did not appear to ... of coronary, cerebrovascular and peripheral vascular events in patients ... in JAMA . However, aspirin did significantly reduce ... The article is being released early online Sunday, November ...
... informed its readers of serious drug reactions and fatalities, which have ... as Heparin. The drug, from Baxter Healthcare, was found to be ... ... Denver (PRWEB) November 9, 2008 -- LegalView.com, the number one legal ...
... they have risk factors that could lead to coronary ... -- Despite certain risk factors, Hispanic patients were 57 ... bypass surgery (CABG) one year after successful angioplasty to ... It also found that Hispanics were less likely to ...
Cached Medicine News:Health News:Sexual intimacy and breast cancer survivors: New research 2Health News:Flu Shots Lower Risk of Blood Clots 2Health News:Flu Shots Lower Risk of Blood Clots 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 2Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 3Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 4Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 2Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 3Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 4Health News:Hispanics Less Likely to Get Repeat Artery Surgery 2
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: